LUMO Lumos Pharma Inc.

Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results after market close on Thursday, March 7, 2024. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.

Investors and the general public are invited to listen to the conference call. To access the call by phone, please click on this complete the form and you will be provided with dial in details and a PIN. To avoid delays, we encourage participants to dial into the conference call ten minutes ahead of the scheduled start time. The webcast may be accessed through this and may also be found in the “Investors & Media” section of the Lumos Pharma website, under “.” A replay of the call will be available after the date of the call and may be accessed through the same link above or found on our website.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$3.4B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit .

Investor & Media Contact:

Lisa Miller

Lumos Pharma Investor Relations

512-792-5454

Source: Lumos Pharma, Inc.



EN
26/02/2024

Underlying

LUMOLumos Pharma Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lumos Pharma Inc.

 PRESS RELEASE
Free
LUMO Lumos Pharma I...

Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Re...

Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months Company to Host Conference Call May 15, 2024, at 8:30AM ET AUSTIN, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therap...

May 14, 2024 1 EN
 PRESS RELEASE
Free
LUMO Lumos Pharma I...

Lumos Pharma to Report First Quarter 2024 Financial Results and Provid...

Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024 AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quarter 2024 financial results before market open on Wednesday, May 15, 2024. The company will host a conference call and webcast at 8:30 AM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. ...

May 9, 2024 1 EN
 PRESS RELEASE
Free
LUMO Lumos Pharma I...

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming...

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe. Pediatric Endocrine Society () Annual Meeting, held May 2-5, 2024, in Chicago, IL Abstract, OraGrowtH210 Trial (P...

April 18, 2024 1 EN
 PRESS RELEASE
Free
LUMO Lumos Pharma I...

Lumos Pharma Announces that the USPTO Has Granted Patent Protection fo...

Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042 AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that on Thursday, March 14, 2024, the Company received a Notice of Allowance from the US Patent and Trade Office (USPTO) for claims in its patent application number PCT/US22/050700 titled “Compactable Oral Formulations of Ibutamoren.” This...

March 20, 2024 1 EN
 PRESS RELEASE
Free
LUMO Lumos Pharma I...

Lumos Pharma Reports Full Year 2023 Financial Results and Provides Cli...

Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Moderate PGHD Met All Primary and Secondary Endpoints Pisit “Duke” Pitukcheewanont, MD, Appointed Chief Medical Officer Conference Call Today at 4:30 PM EST AUSTIN, Texas, March 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a late-stage biopharmaceutical company advancing an oral therapeuti...

March 7, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch